Every material Form 8-K Cellectar Biosciences, Inc. has filed with the SEC since May 18, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Cellectar Biosciences reported a second-quarter 2026 net loss of $6.9 million, or $0.57 per share, up from $5.4 million in the year-earlier quarter, as research and development spending rose on new trials. The company said it started site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström macroglobulinemia and plans a New Drug Application in mid-2027, and it reported cash of $34.0 million, which it says funds operations into the second quarter of 2027.
Net loss of $6.9 million, or $0.57 per share, for the quarter ended June 30, 2026, versus $5.4 million, or $3.39 per share, a year earlier.
Cash and cash equivalents of $34.0 million at June 30, 2026, up from $13.2 million at December 31, 2025, including net proceeds of about $31.7 million from the May 2026 offering.
R&D expenses rose to about $4.6 million from $2.4 million; G&A expenses fell to about $2.6 million from $3.6 million.
Site activation started for the Phase 3 confirmatory study; the New Drug Application is planned for mid-2027.
At its July 7, 2026 annual meeting, Cellectar Biosciences stockholders approved adding 2,000,000 shares to the 2021 Stock Incentive Plan and approved exercising warrants for up to 39,618,078 shares of common stock under Nasdaq rules. Stockholders also elected Andrew Gu and Douglas J. Swirsky to three-year terms and ratified Deloitte & Touche LLP as auditor for fiscal 2026, so the vote could increase the share count available to shareholders.
Plan amendment approved: 1,706,640 for, 439,422 against, 13,825 abstain
Warrant exercise for up to 39,618,078 shares approved: 1,881,936 for, 55,004 against, 222,946 abstain
Andrew Gu and Douglas J. Swirsky elected as Class III directors for three-year terms
Non-binding say-on-pay vote approved: 1,438,422 for, 712,362 against
Cellectar director Stefan Loren will not stand for reelection at the 2026 annual meeting, and the Board appointed Andrew Gu, an analyst at hedge fund Nantahala Capital Management, as a Class III director and Audit Committee member on May 18, 2026. The change follows a May 4, 2026 securities purchase agreement in which Nantahala secured a board designation right, and the filing says Dr. Loren's decision was not due to any disagreement with the Company.
Stefan D. Loren, Ph.D. notified the Board on May 17, 2026 that he will not seek reelection as a Class III director.
Andrew Gu was appointed to the Board as a Class III director and to the Audit Committee on May 18, 2026, as Nantahala's designee.
Dr. Loren will provide consulting services for one year, starting July 8, 2026, for $15,000 per quarter, plus a stock option grant of 15,000 shares at the end of the term.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Cellectar Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →